MNMD Mind Medicine (MindMed) Inc.

XNAS 15.00 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

MNMD $15.00 —

What changed

Recent filings, trades and moves
Key stats
$15.00
52-Week Range
$10.46 – $15.29
YTD
+9.97%
IV Rank (30D)
24.64
Straddle Price
$2.77
P/C Vol Ratio (Feb 20 expiry)
0.15
Market Cap
$1.5B
Open
$15.00
Day Range
$15.00 – $15.00
Prev Close
$15.00
Fair Value
-12.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.00%
Beta vs SPY1.00
Cost of Equity (CAPM)9.50% (VRP-adj)
WACC9.34%
Volatility Risk Premium+349.5pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-55.3%
Book / Price25.5%
Debt / Equity0.12
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$13.20 (Market Anchor value)
SMA 20 / Bollinger Mid$14.52
Bollinger Width / SMA20118.2% (drives anchor stability)
Net Debt$-0.2B
Market Cap$1B
Blended Fair Value
$13.20
Deviation
-12.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $13.20 100% stability 81% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-01 · updated
About
Industry (SIC)
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (2833) · industry map
Exchange
XNAS
Market Cap
$1.5B
Employees
74
List Date
2020-03-03
CIK
0001813814
Last Earnings
Aug 6
Headquarters
New York, NY
Homepage
https://www.mindmed.co

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety diso…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: E earnings, with the move options implied and the move that happened (amber when the stock moved more than implied) · ▲ ▼ insider open-market buys and sales, sized by dollar value · S splits. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Insufficient price history — listed 2446 days ago. Seasonality patterns need at least one full year of data.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $14.52
SMA 50: $13.20
SMA 200: $10.12
Current: $15.00
EMA 12: $14.82
EMA 26: $14.28
MACD: 0.5345 | Signal: -0.0365
BULLISH
ADX (14): 36.82
TREND
+DI: 32.35
−DI: 13.71

Momentum Oscillators

RSI (14): 65.00
NEUTRAL
Stoch %K: 89.09
Stoch %D: 88.33
Williams %R: -8.63

Volume & Volatility

BB Upper: $15.77
BB Lower: $13.28
NEUTRAL
OBV: 83,100,398
Vol SMA 20: 1,157,329
Vol ROC: -100.00%
ATR: $0.43
True Range: $0.00
HV 20: 40.7%
HV 30: 45.3%
HV 60: 58.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-02-01T00:00:00 – 2026-03-16T00:00:00
AI Analysis
Written before MNMD’s Aug 6 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall assessment: BULLISH (confidence level 8/10)

Key drivers:

  • Strong Q2 2025 results driving positive sentiment
  • Robust clinical trial pipeline with multiple key pharmaceutical companies involved
  • Bullish options market signals and high volatility regime

Primary risks:

  • High beta indicating increased risk relative to the broader market
  • Uncertainty surrounding upcoming earnings release (no data available)

Investment thesis: MNMD's strong clinical trial pipeline, combined with recent positive news sentiment, drives our bullish assessment. However, we acknowledge the high risk associated with this stock and recommend a risk-adjusted approach.

Recent news sentiment impact: Positive sentiment has dominated recent headlines, contributing to the stock's upward momentum.

Technical Analysis

Trend Direction:

  • Short-term: Uptrend (1-4 weeks)
  • Medium-term: Uptrend (1-3 months)
  • Long-term: Bullish (3-12 months)

Support/Resistance Levels:

  • Upper Bollinger Band: $15.77
  • Middle Band: $14.52
  • Lower Band: $13.28

Momentum Signals:

  • RSI interpretation: Neutral (65.00), but trending upward
  • MACD signal: Bullish momentum (0.53 / Signal: -0.04 / Histogram: 0.57)
  • Bollinger Bands position: Neutral (middle band at $14.52)

Volume Analysis:

  • Volume SMA 20: 1157329.40
  • On-Balance Volume (OBV): 83100398.00
  • Volume Rate of Change: -100.00% (indicating high volatility and decreasing volume participation)

News & Sentiment Analysis

Recent Headlines Summary:

  • Positive news headlines have dominated recent reporting, driving sentiment and stock price.

Sentiment Assessment:

  • Aggregate sentiment is strongly positive, with multiple recent headlines highlighting MNMD's strong clinical trial pipeline and Q2 2025 results.

Catalyst Identification:

  • Upcoming earnings release (no data available)
  • Ongoing clinical trials and potential partnerships or acquisitions

Market Narrative:

  • Technical signals align with news sentiment, driving the stock's upward momentum. However, we acknowledge that high volatility may lead to increased uncertainty and potential mean reversion.

Risk & Volatility Assessment

Risk Assessment:

  • High risk due to high beta (1.80) and high volatility (0.64)

Volatility Regime:

  • Current regime: High volatility with a historical average true range (ATR) of 40.7%

Options Market Signals:

  • IV Rank: 53.6% (Medium)
  • Current IV: 321.2%
  • Expected Move: $11.22 (35 DTE), 7-DTE: $10.38

Downside Protection:

  • Support levels include the lower Bollinger Band ($13.28) and historical support at $12.50.

Market Context & Positioning

Sector Performance:

  • Psychedelic stocks have performed strongly, with MNMD outperforming its peers.

Institutional Activity:

  • High institutional interest as indicated by volume patterns and options activity.

Correlation Analysis:

  • Stock moves relatively highly correlated to the broader market (R-squared interpretation).

Relative Valuation:

  • Position within trading range: Bullish, above historical averages.

Key Levels & Action Items

Critical Price Levels:

  • Lower Bollinger Band ($13.28)
  • Historical support at $12.50

Breakout/Breakdown Levels:

  • Upper Bollinger Band ($15.77) and recent highs

Time-Sensitive Catalysts:

  • Upcoming earnings release (no data available)

Risk Management:

  • Consider stop-loss levels near the lower Bollinger Band ($13.28) and position sizing considerations based on risk tolerance.

Note: This analysis is based solely on the provided data and should not be taken as personalized investment advice. The reader assumes all risks associated with this report.

Generated
News
All MNMD news →
Earnings History
16 of 16 under expected move
Avg Expected Move
17.96%
Avg Actual Move
3.13%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2022-03-28 Pre-Market 26.05% 1.69% 0.06x Within
2022-05-16 Pre-Market 35.44% 2.64% 0.07x Within
2022-08-11 Pre-Market 3.99% 0.21% 0.05x Within
2022-11-10 Pre-Market 15.35% 7.88% 0.51x Within
2023-03-09 Pre-Market 10.48% 4.79% 0.46x Within
2023-05-04 Pre-Market 16.80% 1.90% 0.11x Within
2023-08-03 Pre-Market 18.52% 2.61% 0.14x Within
2023-11-02 Pre-Market 30.52% 8.43% 0.28x Within
2024-02-28 Pre-Market 23.38% 3.78% 0.16x Within
2024-05-08 Pre-Market 16.44% 0.63% 0.04x Within
2024-08-12 Pre-Market 13.39% 0.87% 0.06x Within
2024-11-07 Pre-Market 13.70% 11.41% 0.83x Within
2025-05-08 Pre-Market 17.07% 1.97% 0.12x Within
2025-07-31 Pre-Market 16.61% 0.66% 0.04x Within
2025-10-29 Pre-Market 19.62% 0.31% 0.02x Within
2026-01-12 Pre-Market 9.93% 0.29% 0.03x Within

Earnings calendar: this week’s reports with expected vs actual moves →

MNMD Options Activity & IV Rank

MNMD IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 73.3%
7-DTE IV: 103.6%
Expected Move: $2.77
7-DTE Move: $0.95
Days to Exp: 37 (2026-02-20)

Options Flow · Feb 20 expiry

Call Volume: 648
Put Volume: 99
P/C Volume: 0.153
BULLISH
Call OI: 4,926
Put OI: 453
P/C OI: 0.092
Total OI: 5,379

ATM Options Pricing

ATM Call: $1.50
ATM Put: $1.27
Call %: 10.0%
Put %: 8.5%

Chain Summary

Chain Volume: 5,298
Chain OI: 71,861
Last Updated: 1/14/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 1st percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
1%
vs own history
GEX tilt
-1.00
OI-weighted, today
Vanna tilt
+0.33
δ-sensitivity to IV
Charm tilt
-0.80
δ-decay vs time
Vanna tilt +0.33: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.80: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 5 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
as of Jan 14 · No data
30 DTE / 10d put —
— pts EXTREME
as of Jan 14 · No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)33.8MediumJan 14
IV Rank (30 DTE)24.6LowJan 14

Embed MNMD IV rank

MNMD's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$2.77Jan 14
Beta Analysis
Insufficient price history — listed 2446 days ago. Beta and correlation vs SPY require ~1 year of daily returns to be statistically meaningful.

MNMD Institutional Ownership (13F)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

# Filer Shares Value % of Total % of Float Period
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

MNMD Insider Trading (Form 4)

Latest: 2025-12-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-12-29 Robert Barrow Chief Executive Officer Sell (S) −25,791 $13.15 -$339.1K EDGAR
2025-12-29 Mark Sullivan Chief Legal Officer Sell (S) −11,276 $13.15 -$148.2K EDGAR
2025-12-29 Daniel Karlin Chief Medical Officer Sell (S) −5,600 $13.15 -$73.6K EDGAR
2025-09-26 Daniel Karlin Chief Medical Officer Sell (S) −7,704 $9.77 -$75.3K EDGAR
2025-09-26 Robert Barrow Chief Executive Officer Sell (S) −25,797 $9.77 -$252.0K EDGAR
2025-09-26 Mark Sullivan Chief Legal Officer Sell (S) −11,278 $9.77 -$110.2K EDGAR
2025-06-26 Mark Sullivan Chief Legal Officer Sell (S) −11,491 $6.80 -$78.1K EDGAR
2025-06-26 Robert Barrow Chief Executive Officer Sell (S) −26,491 $6.80 -$180.1K EDGAR
2025-06-26 Daniel Karlin Chief Medical Officer Sell (S) −7,848 $6.80 -$53.4K EDGAR
2025-06-16 David W Gryska Director Grant (A) +75,187 opt — EDGAR
2025-06-16 Carol A Vallone Director Grant (A) +75,187 opt — EDGAR
2025-06-16 Roger Crystal Director Grant (A) +75,187 opt — EDGAR
2025-06-16 Andreas Krebs Director Grant (A) +75,187 opt — EDGAR
2025-06-16 Suzanne Louise Bruhn Director Grant (A) +75,187 opt — EDGAR
2025-06-02 Brandi Roberts Chief Financial Officer Grant (A) +500,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

MNMD Insider Holdings

9 insiders · @ $15.00
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Robert Barrow Chief Executive Officer 778,477 $11.68M -$1.77M 35 2025-12-29
2 Daniel Karlin Chief Medical Officer 425,025 $6.38M -$607.6K 27 2025-12-29
3 Mark Sullivan Chief Legal Officer 282,576 $4.24M -$569.9K 10 2025-12-29
4 Carrie Liao Chief Accounting Officer 144,923 $2.17M -$46.8K 8 2025-03-26
5 David W Gryska Director 19,851 $297.8K $38.9K 5 2025-06-16
6 Suzanne Louise Bruhn Director 19,623 $294.3K $0 4 2025-06-16
7 Roger Crystal Director 19,623 $294.3K $0 4 2025-06-16
8 Carol A Vallone Director 16,544 $248.2K $0 5 2025-06-16
9 Andreas Krebs Director 15,107 $226.6K $0 5 2025-06-16
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

MNMD Board & Officers

As of SEC filings through Sep 29, 2026

Directors 8

Officers 5

Changes in the last 10 years (26)
Sep 29, 2026Daniel Karlin first listed as a director in an SEC filing
Jan 29, 2026Roger Adsett became a director
Jun 2, 2025Brandi Roberts became Chief Financial Officer
Mar 17, 2025Matthew T. Wiley became Chief Commercial Officer
Jun 21, 2023David W Gryska became a director
Apr 24, 2023Carrie Liao listed as Chief Accounting Officer (previously VP, Controller&Acct Principal) in SEC filings
Apr 15, 2023The company announced the departure of Brigid Makes from the board in an SEC filing
Apr 13, 2023Mark Sullivan became Chief Legal Officer
Aug 11, 2022The company announced the departure of Wernli Miri Halperin from the board in an SEC filing
Aug 11, 2022Suzanne Louise Bruhn became a director
Aug 11, 2022Roger Crystal became a director
May 23, 2022The company announced the departure of Schond L. Greenway as Chief Financial Officer in an SEC filing
May 23, 2022Schond L. Greenway became Chief Financial Officer
Mar 25, 2022Stephen L Hurst reported in an SEC filing no longer being a director
Jan 1, 2022Wernli Miri Halperin became a director
Jan 1, 2022Wernli Miri Halperin became Executive President
Jan 1, 2022Stephen L Hurst became a director
Jan 1, 2022Sarah Y Vinson became a director
Jan 1, 2022Robert Barrow became a director
Jan 1, 2022Robert Barrow became Chief Executive Officer
Not reported recently (4)
  • Carrie Liao · Last reported as Chief Accounting Officer in an SEC filing dated Mar 26, 2025
  • Wernli Miri Halperin · Last reported as Executive President in an SEC filing dated Aug 22, 2024
  • Cynthia W. Hu · Last reported as Chief Legal Officer&Secretary in an SEC filing dated Mar 28, 2022
  • Sarah Y Vinson · Last reported as a director in an SEC filing dated Jan 10, 2022
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.13
TTM Revenue
—
TTM Net Income
$-183.79M
TTM Op. Cash Flow
$-131.56M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '252025-12-31—$-50.44M$-0.50$-42.98M
Q3 '252025-09-30—$-67.27M$-0.78$-29.57M
Q2 '252025-06-30—$-42.74M$-0.50$-29.60M
Q1 '252025-03-31—$-23.35M$-0.35$-29.42M
Q4 '242024-12-31—$-34.74M$-0.42$-25.35M
Q3 '242024-09-30—$-13.68M$-0.27$-17.19M
Q2 '242024-06-30—$-5.85M$-0.26$-19.99M
Q1 '242024-03-31—$-54.40M$-1.14$-16.60M
Q4 '232023-12-31—$-23.86M$-0.59$-20.56M
Q3 '232023-09-30—$-17.92M$-0.45$-16.63M
Q2 '232023-06-30—$-29.13M$-0.76$-13.85M
Q1 '232023-03-31—$-24.82M$-0.65$-13.33M
Q4 2025 • period ending 2025-12-31 • filed 2026-02-26
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.92
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-55.3%
ROA
-41.8%
Div Yield
—
FCF Yield
-10.09%
Debt/Equity
0.12
Current Ratio
—
Market Cap
$1.30B
as of 2026-03-16

MNMD vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
DFTX Definium Therapeutics, Inc. Common Share $4.5B — — +108.6% 25
RGC Regencell Bioscience Holdings Limited Or $2.5B — — −75.9% 12
TRLV Trulieve Cannabis Corp. $1.9B — — −5.2% 15
MNMD Mind Medicine (MindMed) Inc. Common Shar $1.5B — — +10.0% —
CRON Cronos Group Inc. Common Share $1.2B 19.9 +54.7% +25.2% 63
TLRY Tilray Brands, Inc. Common Stock $368M — +15.9% −75.0% 12
SNDL Sundial Growers Inc. Common Shares $340M — — −21.3% 22
ACB Aurora Cannabis Inc. Common Shares $328M — — +13.8% 3
CGC Canopy Growth Corporation Common Shares $243M — +19.1% −52.8% 73
Peer median $809M 19.9 +19.1% −13.2% 18

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
15.05M
SI % of Float
21.96%
Days to Cover
6.62
Short Vol Ratio
42.2%
Free Float
68.56M
Float %
90.1%
Short interest 2025-12-31 • Short volume 2026-01-14 • Float 2025-11-14